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ABSTRACT
Objective: To determine the association between p53 expression and the probability of organ confinement in patients 
with prostate cancer in Sardjito Hospital, Yogyakarta. Material & method: Prostate specimens were obtained from 
patients with clinical stage T1-T2 prostatic adenocarcinoma in Sardjito Hospital between January 2007 and 
December 2008. Samples were processed and immunohistochemically stained in the Department of Anatomical 
Pathology Gadjah Mada University. Probability of organ confinement was determined by updated Partin table 2007 
from preoperative serum PSA level, Gleason Score, and clinical stage. Correlation between p53 expression and 
probability of organ confinement were statistically analyzed by Spearman correlation test. Results: There were 28 
prostate cancer patients eligible for this study. Mean age was 65,19 ± 10,9 (28 - 81) years old. Mean preoperative PSA 
level were 107,13 ± 165,82 (0,20  734,20) ng/ml. Mean number of p53 expression was 97,47 ± 97,27 (5 - 396)/HPF. 
Significant correlation was found between p53 expression and probability of organ confinement (Spearman r = -
0,441; p = 0,019). Conclusion: p53 expression was negatively correlated with the level of organ confinement in 
patients with prostate cancer.
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INTRODUCTION
Prostate cancer is a solid tumor most frequently 
found among males in the United States. Biological 
behavior of prostate cancer is varied and complicating 
the prediction of the course of the disease and 
prognosis of the patient. In the last two decades, 
incidence of prostate cancer worldwide is increasing 
along with increasing life expectancy and widespread 
prostate-specific antigen (PSA) screening. With the 
more popular use of PSA, more prostate cancer cases 
are found and there is a phenomenon of stage 
migration, in which the incidence of cancer in early 
stage is found more frequently than that in previous 
decade. Along with increased probability for surgical 
intervention, prediction of organ confinement 
becomes more important. Prognostic markers in use 
today, such as grading, clinical staging, and PSA level, 
still have limitation in predicting prognosis. Therefore 
molecular biomarkers to predict patients with organ-
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confined prostate cancer becomes necessary.
Somatic mutation of tumor suppressor gene p53 
has been reported as the basis of the pathogenesis of 
several neoplasms (breast, lung, colon, bladder, and 
prostate cancers), and has been proven as the most 
common genetic change occurring in carcinogenesis. 
Several studies have studied the role of p53 in prostate 
cancer. Even though some studies have indicated that 
gene p53 mutation does not commonly occur in early 
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stage prostate cancer, several current studies have 
shown that loss of p53 suppressor function may be an 
important step in disease progression. In addition, 
change of p53 expression in early stage cancer may be 
a prognostic marker. Furthermore, it is recognized that 
p53 mutations may underlie the process of hormone 
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refractory prostate cancer.
The p53 gene is a DNA gene of 20 kb in length, 
located on the short arm of chromosome 17 (17p13l). 
The p53 gene is comprised of 11 exons that code a 393-
amino acid nuclear phosphoprotein (53 kDa). The loss 
of gene p53 allele on short arm of chromosome 17 at 
17p13 often occurs in various types of tumor. The most 
frequent locations of gene mutation in several types of 
tumor are exons 5 to 8. Normal or wild (wt) type p53 
protein has a very short half life, while the mutated 
        
(mt) type has longer half life. Therefore, mutant-
type p53 can be more easily detected using 
immunohistochemical methods, and p53 immuno-
3-5
reactivity is a reflection of gene p53 mutation.
At present it is recognized that p53 functions as a 
tumor suppressor gene in inhibiting growth of tumor 
cells in vitro and in vivo. The p53 gene has an active 
role in the regulation of transition from G1 phase to S 
phase in cell cycle as a response to DNA damage. 
There is supporting evidence that p53 may inhibit 
expression of several genes enhancing the growth of 
cells (such as, c-fos and c-jun) by binding the proteins 
that regulate the cellular transcription process. 
Therefore, gene transcription regulation by p53 may 
play the primary role in negative regulation of cell 
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growth.  Not only controlling cell cycle and DNA 
repair, the p53 gene also plays a role in apoptosis or 
programmed cell death, although its role in prostate 
6
cell apoptosis remains in debate.
Previous studies have proved that there is 
significant correlation between p53 overexpression 
and tumor stage, which indicates that p53 gene 
mutation is the first event in the carcinogenesis of 
prostate cancer. Additionally, there is correlation 
between p53 overexpression with poor differentiation 
and high index of cell proliferation. Furthermore, 
increased p53 expression also correlates with the 
occurrence of metastasis as well as hormone 
3-5
resistance.
OBJECTIVE
This study aims to identify correlation between 
p53 expression and the probability of organ 
confinement based on the Partin tables.
MATERIAL & METHOD
The subjects of this study were all prostate 
adenocarcinoma patients with clinical stage T1 - 2, 
diagnosed between January 1, 2007 and December 31, 
2008, in Sardjito Hospital, Yogyakarta. The inclusion 
criteria were (1) prostate adenocarcinoma patients 
established with histopathological examination, (2) 
the clinical stage of the patients were T1c, T2 (a - c) 
and has been confirmed by urologists (AJCC-TNM, 
2002), (3) pre-operative serum PSA level was 
examined, and (4) the degree of tumor differentiation 
was known (Gleason Score). The exclusion criterion 
was unknown probability of organ confinement due to 
incomplete examination. In this study, Partin tables 
published in 2007 was used to predict the probability 
of organ confinement of each patient, which was 
determined from a combination of serum PSA level, 
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Gleason Score, and clinical stage.
Serum PSA level was measured pre-operatively in 
the Clinical Pathology Laboratory, Sardjito Hospital. 
The degree of differentiation was determined 
according to the Gleason system based on anatomic 
pathology examination to prostate specimens 
obtained from needle biopsy. Clinical stage used in 
this study was the T stage, determined with digital 
rectal examination, based on AJCC-TNM year 2002. 
P53 staining procedure was performed at Anatomic 
Pathology Laboratory, Sardjito Hospital, using anti 
p53 D-O7 monoclonal antibody. p53 expression was 
examined by a single pathologist by counting p53-
containing nuclei in each preparation. The 
examination of each preparation was performed in 
five visual fields, and result was determined from 
those five visual fields. Correlation between p53 
expression and the probability of organ confinement 
was analyzed statistically using bivariate analysis. 
Prior to analysis, data normality test was performed 
using one-sample Kolmogorov-Smirnov technique. 
When the data was normally distributed, bivariate 
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Patients (n) 28
Age (years), mean + SD (interval) 
PSA serum level (ng/ml)
  0  2,5
  2,6  4,0
  4,1  6,0
  6,1  8,0 
  8,1  10,0 
  > 10,0
65,19 ± 10,9 (28 - 81)
2 (7,14%)
1 (3,57%)
0 (0%)
0 (0%)
0 (0%)
25 (89,29%)
Clinical stage (AJCC-TNM 2002)
T1a
T1b
T1c
T2a
T2b
T2c
0 (0%)
0 (0%)
3 (11,53%)
4 (15,38%)
5 (19,23%)
14 (53,84)
Gleason sum
  2 - 4
  5 - 6
  3 + 4
  4 + 3
  8 -10
5 (17,86%)
5 (17,86%)
3 (10,71%)
1 (3,57%)
14 (50%)
Table 1. Subject characteristics.
A
B
Figure 1. P53 expression in patients with prostate 
adenocarcinoma, marked with brown-stained 
nuclei. (A) p53 expression in patients with high 
probability of organ confinement (T2c, t-PSA = 
1,41 ng/ml, Gleason Score = 2 + 3; probability of 
organ confinement = 84%). (B) p53 expression in 
patients with low probability of organ 
confinement (T2c, t-PSA = 50 ng/ml, Gleason 
Score = 4 + 4; probability of  organ confinement 
= 12%).
analysis was performed with Pearson's correlation 
test. In contrast, when the data were not normally 
distributed, Spearman's correlation test was 
employed. Data were analyzed by means of statistical 
analysis program, SPSS version 15.0.
RESULTS
During the study period, there were a total of 28 
males with mean age of 65,19 ± 10,9 (28 - 81) years 
who met the criteria and enrolled as subjects of study. 
The characteristics of the patients can be seen in table 
1. The mean of pre-operative serum PSA level was 
107,13 ± 165,82 (0,20 - 734,20) ng/ml and the mean of 
total p53 expression was 97,47 ± 97,27 (5 - 396)/high 
power field.
18
Figure 2. Correlation between p53 expression and organ 
confinement.
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DISCUSSION
Mutation of tumor suppressor gene p53 is a 
genetic change underlying much of carcinogenesis in 
several types of tumor. A number of studies have 
shown that p53 immunoreactivity is correlated with a 
high histological grade, DNA aneuploidy, and a high 
rate of cell proliferation. Therefore it is also suggested 
to have correlation with prostate cancer 
aggressiveness. In addition, p53 gene mutation is 
expected to correlate with high recurrent risk and 
hormone refractory prostate cancer.
In this study we combined the factors of clinical 
stage, serum t-PSA level and Gleason Score in 
assessing probability of organ confinement (based on 
Partin Tables) and its correlation with p53 expression 
was examined. The result of this study revealed 
statistically significant negative correlation between 
p53 expression and organ confinement probability in 
patients with T1-2 prostate adenocarcinoma patients 
(p < 0,05). This indicates that with higher p53 
expression, probability of organ confinement in 
prostate cancer patients is lower. Higher p53 
expression means higher p53 gene mutation, from 
wild type (wt) p53 with a short half life to a mutated 
type (mt) p53 with longer half life. Results of this 
study confirms that of Downing et al (2001) who 
concluded that gene p53 mutation is related with 
7
prostate cancer progressiveness.  The results also 
confirmed the study by Papadopoulos et al (1996) and 
da Slavov et al (2006), who suggested correlation 
between high p53 expression and more advanced 
8
tumor stage and pathological status.  A study by 
Miyake et al (2008) also concluded that the increase of 
p53 expression is also a predictor in determining 
surgical margin status (SMS), lymph node metastasis 
9
and tumor volume.
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CONCLUSION
P53 expression in the nuclei of prostate 
adenocarcinoma patients may serve as a marker of 
organ confinement probability. Patients with high p53 
immunoreactivity have low probability of organ 
confinement. Therefore, assessment of p53 
expression can be used as additional clinical 
parameter used in assessing prostate cancer 
progressiveness, in addition to serum PSA level, 
Gleason Score, and examination of tumor margins by 
digital rectal examination.
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